Prognostic utility of serum NT-proBNP (fragments 1-76aa and 13-71aa) and galectin-3 in predicting death and re-hospitalisation due to cardiovascular events in patients with heart failure

Zhang, Xi; Wan, Yunxia; Karunathilaka, Nuwan; Chan, W.; Kostner, Karam; Härtel, Günter; Coats, Andrew J.S.; Atherton, J.; Punyadeera, Chamindie

doi:10.1007/s00380-023-02296-z

Cited by 1 publication

(1 citation statement)

References 36 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, a more recent cohort study indicated that in HF patients or those at the risk of HF, before first hospitalization, GDF-15 grants specific information and is highly predictive of hospitalization for HF or all-cause death rate, contributing to more precise risk assessment that can better guide clinical decision making [80]. In addition to NPs, galectin-3 has been suggested as an important biomarker to stratify HF patients [82].…”

Section: Neurohormonal Biomarkersmentioning

confidence: 99%

Neurohumoral Activation in Heart Failure

Manolis,

Manolis

2023

IJMS

View full text Add to dashboard Cite

In patients with heart failure (HF), the neuroendocrine systems of the sympathetic nervous system (SNS), the renin–angiotensin–aldosterone system (RAAS) and the arginine vasopressin (AVP) system, are activated to various degrees producing often-observed tachycardia and concomitant increased systemic vascular resistance. Furthermore, sustained neurohormonal activation plays a key role in the progression of HF and may be responsible for the pathogenetic mechanisms leading to the perpetuation of the pathophysiology and worsening of the HF signs and symptoms. There are biomarkers of activation of these neurohormonal pathways, such as the natriuretic peptides, catecholamine levels and neprilysin and various newer ones, which may be employed to better understand the mechanisms of HF drugs and also aid in defining the subgroups of patients who might benefit from specific therapies, irrespective of the degree of left ventricular dysfunction. These therapies are directed against these neurohumoral systems (neurohumoral antagonists) and classically comprise beta blockers, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers and vaptans. Recently, the RAAS blockade has been refined by the introduction of the angiotensin receptor–neprilysin inhibitor (ARNI) sacubitril/valsartan, which combines the RAAS inhibition and neprilysin blocking, enhancing the actions of natriuretic peptides. All these issues relating to the neurohumoral activation in HF are herein reviewed, and the underlying mechanisms are pictorially illustrated.

show abstract

Section: Neurohormonal Biomarkersmentioning

confidence: 99%